Viewing Study NCT00312754



Ignite Creation Date: 2024-05-05 @ 4:48 PM
Last Modification Date: 2024-10-26 @ 9:24 AM
Study NCT ID: NCT00312754
Status: TERMINATED
Last Update Posted: 2016-09-19
First Post: 2005-11-14

Brief Title: A Phase IV Study of BMS-232632 in HIV Patients With Metabolic Syndrome
Sponsor: Bristol-Myers Squibb
Organization: Bristol-Myers Squibb

Study Overview

Official Title: A Phase IV One-arm Open-label Multicenter Study Evaluating Effect of Treatment Change to AtazanavirRitonavir on Brachial Endothelial Function of HIV Infected Patient Receiving Function in HIV Infected Patient Receiving Potent Antiretroviral Combination Therapy
Status: TERMINATED
Status Verified Date: 2016-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: insufficient enrollment
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this clinical research study is to learn if BMS-232632 administered as Atazanavirritonavir ATVRTV is superior to an anti-retroviral regimen including Lopinavirritonavir LPVRTV as assessed by an increased brachial artery flow-mediated vasodilatation FMD in HIV-infected patients The safety of this treatment will also be studied
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
Amazone None None None